Orthogen AG is a pioneering biotech company specializing in molecular and autologous medicine, with a focus on developing patented platform technologies for targeted therapies. Their innovative approaches are designed to address chronic diseases linked to inflammation, oxidative stress, and tissue injury. The company has over 25 years of research experience and has conducted more than 400,000 treatments globally, contributing to a significant body of scientific literature. Orthogen's technologies are applicable across various fields, including orthopedics, veterinary medicine, and aesthetics, reflecting their commitment to enhancing patient care through advanced medical solutions.

The core of Orthogen's research lies in the integration of regenerative medicine and biomolecular science, emphasizing the importance of understanding biomolecular changes as fundamental mechanisms in various diseases and tissue aging. Their unique methodologies focus on harnessing the body's own immune system to stimulate and harvest autologous mediators, such as growth factors and cytokines, which serve as therapeutic agents. By targeting the underlying causes of diseases rather than merely managing symptoms, Orthogen aims to restore homeostasis and improve long-term clinical outcomes across a wide range of conditions, including osteoarthritis, autoimmune diseases, and dermatological disorders.

Germany

Orthogen AG is a privately held, research-based biotech company, founded in Düsseldorf, Germany. Orthogen has developed patented medical platform technologies that are standardized and simple to use for targeted therapies in the field of autologous and regenerative medicine.

Orthogen

Company Details